Fidaxomicina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fidaxomicina" in Italian language version.

refsWebsite

Global rank Italian rank

2^nd place

7^th place

799^th place

22^nd place

4^th place

9^th place

1^st place

4,294^th place

low place

2,836^th place

107^th place

8,069^th place

6,596^th place

doi.org

P. Revill, N. Serradell e J. Bolós, Tiacumicin B, in Drugs of the Future, vol. 31, n. 6, 2006, p. 494, DOI:10.1358/dof.2006.031.06.1000709.
Fidaxomicin, in Drugs in R&D, vol. 10, 2012, p. 37, DOI:10.2165/11537730-000000000-00000.
T. J. Louie, J. Emery, W. Krulicki, B. Byrne e M. Mah, OPT-80 Eliminates Clostridium difficile and is Sparing of Bacteroides Species during Treatment of C. Difficile Infection, in Antimicrobial Agents and Chemotherapy, vol. 53, n. 1, 2008, pp. 261-3, DOI:10.1128/AAC.01443-07, PMC 2612159, PMID 18955523.
Stuart Johnson, Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes, in Journal of Infection, vol. 58, n. 6, 2009, pp. 403-10, DOI:10.1016/j.jinf.2009.03.010, PMID 19394704.
Aashish Srivastava, Meliza Talaue, Shuang Liu, David Degen, Richard Y Ebright, Elena Sineva, Anirban Chakraborty, Sergey Y Druzhinin, Sujoy Chatterjee, Jayanta Mukhopadhyay, Yon W Ebright, Alex Zozula, Juan Shen, Sonali Sengupta, Rui Rong Niedfeldt, Cai Xin, Takushi Kaneko, Herbert Irschik, Rolf Jansen, Stefano Donadio, Nancy Connell e Richard H Ebright, New target for inhibition of bacterial RNA polymerase: 'switch region', in Current Opinion in Microbiology, vol. 14, n. 5, 2011, pp. 532-43, DOI:10.1016/j.mib.2011.07.030, PMC 3196380, PMID 21862392.

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC, su news-medical.net, Optimer Pharmaceuticals, 16 settembre 2009. URL consultato il 7 maggio 2013.

T. J. Louie, J. Emery, W. Krulicki, B. Byrne e M. Mah, OPT-80 Eliminates Clostridium difficile and is Sparing of Bacteroides Species during Treatment of C. Difficile Infection, in Antimicrobial Agents and Chemotherapy, vol. 53, n. 1, 2008, pp. 261-3, DOI:10.1128/AAC.01443-07, PMC 2612159, PMID 18955523.
Stuart Johnson, Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes, in Journal of Infection, vol. 58, n. 6, 2009, pp. 403-10, DOI:10.1016/j.jinf.2009.03.010, PMID 19394704.
Aashish Srivastava, Meliza Talaue, Shuang Liu, David Degen, Richard Y Ebright, Elena Sineva, Anirban Chakraborty, Sergey Y Druzhinin, Sujoy Chatterjee, Jayanta Mukhopadhyay, Yon W Ebright, Alex Zozula, Juan Shen, Sonali Sengupta, Rui Rong Niedfeldt, Cai Xin, Takushi Kaneko, Herbert Irschik, Rolf Jansen, Stefano Donadio, Nancy Connell e Richard H Ebright, New target for inhibition of bacterial RNA polymerase: 'switch region', in Current Opinion in Microbiology, vol. 14, n. 5, 2011, pp. 532-43, DOI:10.1016/j.mib.2011.07.030, PMC 3196380, PMID 21862392.

Dificid, Full Prescribing Information (PDF), su dificid.com, Optimer Pharmaceuticals, 2013 (archiviato dall'url originale il 26 giugno 2011).
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment, su reuters.com, Optimer Pharmaceuticals, 17 maggio 2009. URL consultato il 7 maggio 2013 (archiviato dall'url originale il 14 novembre 2012).